Q‑VANT Biosciences offers a platform for the research, development, and large‑scale manufacturing of standardized saponin adjuvants using its proprietary Q‑SAP technology. By sourcing quillaja biomass from diverse plant materials and providing GMP‑certified, pharma‑grade adjuvants together with a target product profile tool and regulatory‑ready dossiers, the company enables vaccine developers to accelerate formulation, reduce development timelines, and secure sustainable, high‑quality supply for human and veterinary vaccines.
Funding
Funding not disclosed
Founders
Product
Problem
Vaccine developers face limited and inconsistent supplies of high‑quality quillaja saponin adjuvants, which hampers formulation optimization, increases costs, and creates regulatory hurdles for new and existing vaccines.
Solution
Q‑VANT Biosciences provides a platform for the research, development, and large‑scale manufacturing of standardized saponin adjuvants using its proprietary Q‑SAP technology. By sourcing biomass from a broad range of quillaja plant materials and employing controlled cell‑culture processes, the company can produce pharma‑grade adjuvants at volumes up to 1,000‑fold greater than traditional bark extraction. The platform offers a searchable target product profile tool that matches the most suitable saponin variant to a given antigen, disease indication, and co‑adjuvant combination, accelerating formulation work and reducing development timelines. Q‑VANT also supplies a regulatory‑ready dossier and GMP‑compliant audit package, simplifying clinical trial approval and market authorization. The integrated approach delivers a sustainable, scalable supply chain that lowers the environmental footprint while ensuring consistent product quality for both human and veterinary vaccines.
Target Audience
Primary customers are pharmaceutical companies and vaccine developers seeking reliable, high‑quality saponin adjuvants for human or veterinary vaccine formulations.
Features
- Q‑SAP proprietary technology enabling high‑yield extraction from diverse quillaja plant sources, increasing production capacity by up to 1,000×
- GMP‑certified manufacturing facility delivering pharma‑grade saponin adjuvants with batch‑to‑batch consistency
- Target product profile database that recommends optimal saponin variants based on antigen type, disease, and co‑adjuvant requirements
- Full regulatory support package, including standardized dossiers and audit documentation for fast clinical trial and marketing approvals
- Sustainable sourcing strategy reducing reliance on bark harvest and minimizing ecological impact
- Custom formulation services for both human and veterinary vaccine developers